Literature DB >> 7405805

Entry of quinidine into cerebrospinal fluid.

H R Ochs, D J Greenblatt, B L Lloyd, E Woo, M Sonntag, T W Smith.   

Abstract

Some of the unwanted effects of quinidine commonly occurring in clinical practice involve the central nervous system. We therefore assessed the rate and extent of quinidine passage into cerebrospinal fluid (CSF) in humans and dogs. In eight human subjects receiving oral quinidine therapy, lumbar CSF quinidine concentrations averaged 16% of unbound serum concentrations (range: 4% to 37%). The findings were confirmed when simultaneous serum (total and unbound) and CSF quinidine concentrations were followed for up to 8 hours after a single intravenous dose of quinidine in anesthetized dogs. Quinidine appeared promptly in CSF of all animals, but CSF concentrations averaged only 37% to 46% of unbound serum levels. The in vitro octanol:water partition coefficient for quinidine at physiologic pH was greater than 100, indicating that unbound quinidine should readily traverse the blood-brain barrier. Thus, passage of quinidine into CSF appears not to be governed by passive diffusion alone. Quinidine may participate in an active transport system such as that which removes certain other basic substances from CSF.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7405805     DOI: 10.1016/0002-8703(80)90148-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

2.  Regional Differences in the Absolute Abundance of Transporters, Receptors and Tight Junction Molecules at the Blood-Arachnoid Barrier and Blood-Spinal Cord Barrier among Cervical, Thoracic and Lumbar Spines in Dogs.

Authors:  Hina Takeuchi; Masayoshi Suzuki; Ryohei Goto; Kenta Tezuka; Holger Fuchs; Naoki Ishiguro; Tetsuya Terasaki; Clemens Braun; Yasuo Uchida
Journal:  Pharm Res       Date:  2022-04-29       Impact factor: 4.200

Review 3.  Rational Small Molecule Treatment for Genetic Epilepsies.

Authors:  Ethan M Goldberg
Journal:  Neurotherapeutics       Date:  2021-08-24       Impact factor: 6.088

4.  Treatment Responsiveness in KCNT1-Related Epilepsy.

Authors:  Mark P Fitzgerald; Martina Fiannacca; Douglas M Smith; Tracy S Gertler; Boudewijn Gunning; Steffen Syrbe; Nienke Verbeek; Hannah Stamberger; Sarah Weckhuysen; Berten Ceulemans; An-Sofie Schoonjans; Massimiliano Rossi; Geneviève Demarquay; Gaetan Lesca; Kern Olofsson; D A Koolen; Frauke Hornemann; Stephanie Baulac; Guido Rubboli; Kelly Q Minks; Bohoon Lee; Ingo Helbig; Dennis Dlugos; Rikke S Møller; David Bearden
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

5.  Quinidine in the treatment of KCNT1-positive epilepsies.

Authors:  Mohamad A Mikati; Yong-Hui Jiang; Michael Carboni; Vandana Shashi; Slave Petrovski; Rebecca Spillmann; Carol J Milligan; Melody Li; Annette Grefe; Allyn McConkie; Samuel Berkovic; Ingrid Scheffer; Saul Mullen; Melanie Bonner; Steven Petrou; David Goldstein
Journal:  Ann Neurol       Date:  2015-11-18       Impact factor: 10.422

6.  Entry of diazepam and its major matabolite into cerebrospinal fluid.

Authors:  D J Greenblatt; H R Ochs; B L Lloyd
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

7.  Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.

Authors:  Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel
Journal:  Arch Toxicol       Date:  2021-07-15       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.